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Background and Objectives. Cardiovascular disease (CVD) is a leading cause of death among military veterans with several 
reports suggesting a link between combat and related traumatic injury (TI) to an increased CVD risk. e aim of this paper is 
to conduct a widespread systematic review and meta-analysis of the relationship between military combat ± TI to CVD and its 
associated risk factors. Methods. PubMed, EmbaseProQuest, Cinahl databases and Cochrane Reviews were examined for all 
published observational studies (any language) reporting on CVD risk and outcomes, following military combat exposure ± TI 
versus a comparative nonexposed control population. Two investigators independently extracted data. Data quality was rated 
and rated using the 20-item AXIS Critical Appraisal Tool. e risk of bias (ROB using the ROBANS 6 item tool) and strength 
of evidence (SOE) were also critically appraised. Results. From 4499 citations, 26 studies (14 cross sectional and 12 cohort; 
78–100% male) met the inclusion criteria. e follow up period ranged from 1 to 43.6 years with a sample size ranging from 
19 to 621901 participants in the combat group. Combat-related TI was associated with a signi£cantly increased risk for CVD 
(RR 1.80: 95% CI 1.24–2.62; 퐼2 = 59%, 푝 = 0.002) and coronary heart disease (CHD)-related death (risk ratio 1.57: 95% CI 
1.35–1.83; 퐼2 = 0%, 푝 = 0.77: 푝 < 0.0001), although the SOE was low. Military combat (without TI) was linked to a marginal, 
yet signi£cantly lowe-r pooled risk (low SOE) of cardiovascular death in the active combat versus control population (RR 0.90: 
CI 0.83–0.98; 퐼2 = 47%, 푝 = 0.02). ere was insu¦cient evidence linking combat ± TI to any other cardiovascular outcomes 
or risk factors. Conclusion. ere is low SOE to support a link between combat-related TI and both cardiovascular and CHD-
related mortality. ere is insu¦cient evidence to support a positive association between military combat ± any other adverse 
cardiovascular outcomes or risk factors. Data from well conducted prospective cohort studies following combat are needed.
1. Introduction
In 1979 US Veterans Administration published the results of 
their review examining the potential causal relationship 
between traumatic limb amputation and future risk of cardi-
ovascular disease (CVD) [1]. As part of this work a literature 
review was undertaken to examine the medical literature relat-
ing to traumatic amputation and future CVD risk. Among the 
publications examined were just six studies [2–7] that had 
reported cardiovascular outcomes (including hypertension 
and cardiovascular death) following traumatic amputation. 
e results were inconsistent and failed to show a clear 
relationship.
Owing to the inconsistency of existing published data, 
coupled with their concern regarding the health implications 
of a potential link between increased CVD risk, combat- 
related amputations and potentially other forms of severe 
traumatic injury (TI), the Veteran’s Administration concluded 
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that more robust data was required. Consequently, the 
Veteran’s Administration and Department of US Defence com-
missioned a longitudinal study to more robustly investigate 
the issue. is retrospective cohort study was the ﬁrst to pro-
vide evidence to support a signiﬁcant link between combat- 
related traumatic amputation and a higher risk of future 
adverse cardiovascular outcomes [8, 9]. Unfortunately, this 
data represented military populations who were injured more 
than seventy years ago, and the relevance for those injured in 
current conﬂicts is open to question. Subsequent to this, only 
one systematic review and one literature review have emerged. 
ey were both published approximately 10 years ago, only 
identiﬁed a handful of additional studies and failed to reach a 
consensus opinion [10, 11].
Consequently, and in light of the high tempo and large 
scale of recent military conﬂicts, there is a need to re-examine 
the issue of combat related injury and CVD risk. Recent wars 
in Iraq and Afghanistan have led to the survival of large num-
bers of combatants, who have sustained highly complex and 
severe trauma, which would most likely have proved fatal as 
little as 20 years ago. Despite this, there has not been a wider 
examination of the impact of unselected combat on CVD out-
come (e.g., cardiovascular death) and its associated risk factors 
(e.g., hypertension and lipid proﬁles).
e objective of this review was to systematically search 
and review the literature to determine whether military com-
bat exposure, both with and separately without TI is linked to 
an increased CVD risk and adverse outcomes.
2. Methods
2.1. Search Strategy. We conducted a systematic review and 
meta-analysis according to a pre-deﬁned protocol and in 
accordance to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [12]. 
e protocol of this review was prospectively registered at 
PROSPERO. Four electronic databases were used: PubMed, 
Embase, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and ProQuest. Cochrane Reviews was 
also searched to identify any previous systematic reviews. 
A systematic search was undertaken for articles published 
between the 1st of January 1980 and 22nd December 2018, 
in any language. Two reviewers (NDV and CJB) worked 
in conjunction with a Medical Librarian to create a search 
algorithm, which used Medical Subject Headings (MeSH) 
terms, where available.
e search was conducted in adherence to the PICO 
(Population, Intervention/exposure, Comparison/control and 
Outcome) tool [13]. e population search terms examined 
were (“Military”, “veterans”, “combat”, “servicemen”, “Iraq”, 
“Afghanistan”, “Army”, “armed services”, “marines” or “infan-
try”). e Intervention search terms used were (“traumatic”, 
“trauma-related”, “amputation”, “amputees”, “traumatic injury”, 
“wounded”, “wounding”, “combat”, “warfare”, or “battleﬁeld”). 
e Outcome search terms were cardiovascular (including 
“Cardiovascular death”, “cardiovascular event”, “cardiovascular 
mortality” and “cardiovascular Risk” and related terms (“cor-
onary heart disease (CHD)”, “ischemic heart disease”, 
“coronary artery disease”, “myocardial infarction”, “acute cor-
onary syndrome”, “Peripheral arterial disease”, “peripheral 
vascular disease”, “atrial ﬁbrillation”, “arterial hypertension”, 
“high blood pressure”, “atrial ﬁbrillation”, “heart failure”, 
“stroke”, “aortic aneurysm”, “coronary artery bypass” “coronary 
artery intervention”, “coronary artery stenting”, “diabetes mel-
litus”, “metabolic syndrome”, “carotid intimal thickness”, “aug-
mentation index”, “arterial stiﬀness” or “pulse wave velocity” 
or “pulse waveform analysis”). e reference sections of eligi-
ble full-text articles were also examined to identify additional 
studies suitable for inclusion that might have been missed by 
the search algorithm.
2.2. Study Selection. Only observational studies that evaluated 
the impact of combat exposure ± TI on future cardiovascular 
outcomes were included. Individual case reports, conference 
abstracts, animal studies, in vivo/in vitro studies and those 
involving children, were excluded. Studies relating to 
starvation, cold injury or famine were excluded. Studies that 
examined selected groups of combatants with traumatic brain 
injury, spinal cord injury and post-traumatic stress disorder 
(PTSD) were also excluded.
All selected studies needed to include a population of cur-
rently serving, or ex-military and predominantly (>75%) male 
servicemen (veterans) who had been exposed to combat oper-
ations. A Comparator or Control group of nonexposed con-
trols was required with a period of follow up from exposure 
to outcome of at least one year (see selection algorithm 
Supplement Table 1).
Two reviewers (CJB and NDV) examined all of the 
screened records independently to determine potential for 
inclusion. For each study a preliminary grading of “include, 
exclude or unclear” was made. Study eligibility was assessed 
on the basis of the article title, followed by examination of the 
abstract. Aer the preliminary screening process, full text ver-
sions of articles deemed “included” and “unclear” were scru-
tinised further. Eligible studies were identiﬁed based on the 
inclusion criteria. Any disagreements between reviewers were 
resolved by a detailed discussion in order to come to a con-
sensus. e PRISMA ﬂowchart for the selection of included 
studies is shown in Figure 1.
2.3. Data Collection and Abstraction. Following selection, the 
data for each study was extracted using a pre-designed data 
extraction form, which included author, year of publication, 
military conﬂict and population studied, number of 
participants, type of study, sex, duration of follow up, study 
outcomes and ﬁndings (Table 1).
2.4. Quality Assessment. e AXIS Critical Appraisal tool was 
used to critically appraise the quality of each of the included 
studies [14] (Supplement Table 2). e AXIS tool consists of 
20 questions relating to study conduct. Studies with a total 
score of >15 were deemed to be high quality, those of 10–15 
of moderate quality, whilst those scoring <10 were deemed 
poor quality. e Risk of Bias (ROB) of all included studies 
was examined using the Risk of Bias Assessment Tool for 
Nonrandomized Studies (RoBANS), which consists of six 
questions (Supplement Table 3) [15]. Using the total scores for 
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each study the ROB was graded as low (scores of 0), moderate 
(1-2) or high (>2).
2.5. Study Outcomes. e study outcomes were cardiovascular 
death, CHD-related death, CHD and myocardial infarction, 
arterial hypertension, atrial £brillation, stroke, heart failure, 
aortic aneurysms, peripheral vascular disease, diabetes 
mellitus, metabolic syndrome, carotid intima medial thickness 
and measures of arterial sti¬ness (including augmentation 
index and pulse wave velocity).
2.6. Statistical Analysis. Due to the heterogeneity of the 
included studies (cross sectional and cohort designs, mode 
of data presentation, etc.) a pooled analysis was inappropriate 
for the majority of the reported data. Accordingly, a narrative 
synthesis was undertaken for most included studies. A meta-
analysis was undertaken separately for the binary outcome 
of CVD and CHD-related death, as these outcomes were 
only reported from cohort studies. Data was pooled using a 
random-e¬ects model and the Cochran–Mantel–Haenszel 
Estimate for the generation of weighted risk ratios and their 
95% con£dence intervals.
Analysis of continuous data was undertaken using 
GraphPad Prism® (version 6.07) with results presented as the 
mean ± standard deviation (SD). Meta-analyses were con-
ducted using RevMan (Review Manager) so°ware (Version 
5.3). Heterogeneity was evaluated using forest plots and the 퐼2
statistic; 퐼2 values of 25%, 50%, and 75% were considered evi-
dence of low, moderate, and high heterogeneity, respectively 
[16]. e overall strength of evidence (SOE) for the included 
studies was assessed using the £ve domains of consistency, 
precision, reporting bias, study limitations and directness, as 
supported by the Cochrane Collaboration Tool [17] . e over-
all SOE was rated by a single investigator (CJB) with a £nal 
rating of high, moderate, low, or insu¦cient as previously 
described [18].
3. Results
e initial search retrieved 4499 potentially relevant studies, 
from which 345 duplicates were removed immediately. 
Following the preliminary title and abstract review, 73 full-text 
articles were screened for eligibility. Forty eight full-text arti-
cles failed to fully meet the systemic review inclusion criteria 
and were excluded. One additional study, which met our selec-
tion criteria, was identi£ed from the reference lists (Figure 1) 
and included. Hence, 26 studies were included in this review. 
Agreement between the two reviewers on the selection of full-
text articles was moderate Cohens Cohen’s 휅 0.70 (86.3% 
agreement).
3.1. Study Characteristics. All of the included studies were 
observational, 14 being cross sectional and 12 being cohort 
studies (Table 1). e follow up period ranged from 1 to 43.6 
years. e sample size of the combat exposed population 
ranged from 19 to 621901 participants. One study was 
published in French. Fourteen studies related to US military 
war veterans (Table 1); other represented populations included 
UK, Iranian, Israeli, German and Finnish veterans. e studies 
Records identied via database searching (n = 4499)
Embase (n = 1587)
Pubmed (n = 1786)
Proquest (n = 995)
Cinhal (n = 131) 
Cochrane reviews (n = 0) 
Tittles and abstracts screened 
(n = 4154)
Full text articles assessed for eligibility
(n = 73)
Studies in qualitative synthesis 
(n = 26)
Under 'records excluded due 
to incorrect study population',
exposure or outcomes (n = 4081)
Duplicates removed (n = 345) 
Records excluded (n = 48) 
-combat burden unreported (n = 7)
-Incorrect comparators (n = 10)
wrong outcomes (n = 7)
-Nonmilitary (n = 3)
-No active control (n = 15)
-Noncombat (n = 6)
Identied in reference lists (n = 1)
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Figure 1: PRISMA ¸ow diagram representing search and selection of studies.
International Journal of Vascular Medicine4
Ta
bl
e 
1:
 D
es
cr
ip
tio
n 
of
 in
di
vi
du
al
 st
ud
ie
s a
nd
 th
ei
r o
ut
co
m
es
 an
d 
£n
di
ng
s.
Au
th
or
 y
ea
r
Po
pu
la
tio
n
N
um
be
rs
 an
d 
ty
pe
 o
f 
ex
po
su
re
St
ud
y 
de
sig
n
A
ge
 in
 y
ea
rs
M
al
e, 
%
 in
 
co
m
ba
t g
ro
up
Fo
llo
w
 
up
O
ut
co
m
es
Ke
y 
£n
di
ng
/c
ov
ar
ia
te
 ad
ju
stm
en
t
Co
m
ba
t +
 tr
au
m
at
ic 
in
ju
ry
H
ru
be
c a
nd
 
Ry
de
r 1
98
0 
[9
]
U
S 
m
ili
ta
ry
 W
W
II
 
(1
94
4–
45
) v
et
er
an
s
38
90
 p
ro
xi
m
al
 am
pu
te
es
Re
tro
sp
ec
tiv
e 
co
ho
rt
>8
0%
 <
30
 y
ea
rs
 o
ld
 at
 
tim
e o
f i
nj
ur
y
10
0%
≥3
0 
ye
ar
s
A
ll-
ca
us
e a
nd
 
di
se
as
e s
pe
ci
£c
 
m
or
ta
lit
y
↑ adjuste
d 
al
l-c
au
se
 (R
R 
: 1
.3
6 :
 1.
25
–1
.4
8)
 
CV
D
 (R
R 
: 1
.5
8 :
 1.
40
–1
.7
9)
 an
d 
CH
D
 
re
la
te
d 
de
at
h 
(R
R 
: 1
.5
6 :
 1.
36
–1
.7
9)
 am
on
g 
pr
ox
im
al
 am
pu
te
es
 v
s. 
in
ju
re
d.
  
↑ risk of
 al
l-c
au
se
 (1
.2
9 :
 1.
18
–1
.4
1)
, C
V
D
 
(1
.4
4 :
 1.
26
–1
.6
4)
 an
d 
CH
D
 (1
.4
5 :
  
1.
24
–1
.6
8)
 d
ea
th
 am
on
g 
pr
ox
im
al
 v
s d
is-
ta
l a
m
pu
te
es
 an
d 
vs
 g
en
er
al
 p
op
ul
at
io
n.
29
17
 d
ist
al
 am
pu
te
es
3 
gr
ou
ps
 ag
e m
at
ch
ed
38
90
 in
ju
re
d
A
ge
s a
t a
na
ly
sis
 n
ot
 
pr
ov
id
ed
U
S 
po
pu
la
tio
n 
(a
ge
 
m
at
ch
ed
)
La
bo
ur
et
 et
 al
. 
19
87
 [3
5]
Fr
en
ch
 v
et
er
an
s
10
6 
w
ith
 co
m
ba
t r
el
at
ed
 
am
pu
ta
tio
n 
(4
9 
A
KA
)
Cr
os
s-
se
ct
io
na
l
C
om
pa
re
d 
by
 ag
e d
ec
-
ad
es
 fr
om
 4
0–
89
 ye
ar
s
10
0%
>1
5 
ye
ar
s
Sy
sto
lic
 an
d 
di
as
to
lic
 b
lo
od
 
pr
es
su
re
H
ig
he
r u
na
dj
us
te
d 
pr
ev
al
en
ce
 o
f s
ys
to
lic
 
(n
ot
 d
ia
sto
lic
) H
TN
 in
 th
e a
m
pu
te
es
 v
s 
co
nt
ro
ls 
(5
6%
 v
s. 
29
%
; 푝
<
0.0
2)
 an
d 
 
sig
ni
£c
an
t f
or
 ea
ch
 ag
e d
ec
ad
e  
co
m
pa
ris
on
W
W
I (
19
14
) 푛
=
23
18
4 
ag
e m
at
ch
ed
 co
nt
ro
ls 
w
ith
ou
t H
TN
W
W
II
 (1
93
9)
 
푛
=
67
O
th
er
 푛
=
16
Ro
se
 et
 al
. 1
98
7 
[3
6]
U
S 
Vi
et
na
m
 W
ar
 
ve
te
ra
ns
19
 A
KA
Cr
os
s-
se
ct
io
na
l
20
–2
2 
at
 in
ju
ry
 an
d 
35
–3
6 
ye
ar
s a
t a
na
ly
sis
10
0%
≥1
5 
ye
ar
s
In
su
lin
 re
sp
on
se
 
to
 g
lu
co
se
 in
fu
-
sio
n
↑ unadju
ste
d 
ra
te
 o
f H
TN
 (1
0/
19
) i
n 
am
pu
te
es
 v
s c
on
tro
ls 
(1
/1
2;
 푝
<
0.0
5)
; n
o 
di
¬e
re
nc
e l
ip
id
 le
ve
ls
12
 ag
e m
at
ch
ed
 co
nt
ro
ls
Vo
llm
ar
 et
 al
. 
19
89
 [3
4]
G
er
m
an
 W
W
II
 
(1
93
9–
19
45
) v
et
-
er
an
s
32
9 
ve
te
ra
ns
 w
ith
 A
KA
Cr
os
s-
se
ct
io
na
l
67
.2
 y
ea
rs
 A
KA
10
0%
43
.8
 
ye
ar
s 
fro
m
 
in
ju
ry
U
ltr
as
ou
nd
 
di
ag
no
sis
 o
f 
in
fr
ar
en
al
 ab
-
do
m
in
al
 ao
rt
ic
 
an
eu
ry
sm
s
↑ AKA i
n 
am
pu
te
es
 v
s c
on
tro
ls 
(5
.8
%
 
vs
. 1
.1
%
); 
no
 d
i¬
er
en
ce
s i
n 
ris
k 
of
 H
TN
, 
hy
pe
rli
pi
de
m
ia
 an
d 
D
M
 (c
om
pa
ra
tiv
e 
da
ta
 n
ot
 re
po
rt
ed
)
70
2 
no
na
m
pu
te
e v
et
er
an
s
68
.1
 y
ea
rs
 co
nt
ro
ls 
w
ith
 
co
m
pa
ra
bl
e b
ur
de
n 
of
 
CV
D
 ri
sk
 fa
ct
or
s
Ye
ku
tie
l e
t a
l. 
19
89
 [2
6]
Is
ra
eli
 W
ar
 V
et
er
an
s 
w
ar
s (
19
48
–9
, 1
95
6,
 
19
67
, 1
97
3)
53
 tr
au
m
at
ic
 lo
w
er
 li
m
b 
am
pu
te
es
Cr
os
s-
se
ct
io
na
l
57
.2
 y
ea
rs
10
0%
≥2
0 
ye
ar
s 
fro
m
 
in
ju
ry
H
yp
er
te
ns
io
n,
 
CH
D
 an
d 
D
M
↑ unadju
ste
d 
pr
ev
al
en
ce
 o
f C
H
D
 in
  
am
pu
te
es
 v
s c
on
tro
ls 
(3
2.
1%
 v
s. 
18
.2
%
; 
푝
<
0.0
1) 
an
d 
D
M
 (2
2.
6%
 v
s. 
9.
4%
); 
no
 
di
¬e
re
nc
e i
n 
H
TN
 (3
5.
8%
 v
s. 
35
.2
%
)
15
9 
ag
e a
nd
 se
x-
m
at
ch
ed
 
co
nt
ro
ls
Lo
re
nz
 et
 al
. 
19
94
 [2
5]
G
er
m
an
 p
op
ul
at
io
n 
co
n¸
ic
ts 
no
t s
ta
te
d
22
6 
ve
te
ra
ns
 w
ith
 tr
au
m
at
ic
 
lo
w
er
 li
m
b 
am
pu
ta
tio
ns
Cr
os
s-
se
ct
io
na
l
A
ge
 n
ot
 re
po
rt
ed
 (s
ho
rt
 
re
po
rt
)
N
ot
 re
po
rt
ed
U
nr
e-
po
rt
ed
 
bu
t >
1 
ye
ar
U
ltr
as
ou
nd
 
di
ag
no
sis
 o
f 
ab
do
m
in
al
 ao
rt
ic
 
an
eu
ry
sm
s
N
o 
di
¬e
re
nc
e i
n 
pr
ev
al
en
ce
 o
f a
or
tic
 
an
eu
ry
sm
s a
m
on
g 
am
pu
te
es
 (4
.4
%
) v
s 
co
nt
ro
ls 
(4
%
). 
N
o 
di
¬e
re
nc
e i
n 
ris
k 
of
 
hy
pe
rt
en
sio
n,
 d
ia
be
te
s o
r h
yp
er
lip
id
em
ia
19
9 
co
nt
ro
ls
Pe
le
s e
t a
l. 
19
95
 [4
3]
Is
ra
el 
de
fe
nc
e f
or
ce
 
ve
te
ra
ns
 1
94
8–
19
74
52
 A
m
pu
te
es
Cr
os
s-
se
ct
io
na
l
A
m
pu
te
es
 5
2 
ye
ar
s c
on
-
tro
ls 
53
 y
ea
rs
10
0%
33
 y
ea
rs
 
a°
er
 
in
ju
ry
In
su
lin
 re
sis
t-
an
ce
 an
d 
au
to
-
no
m
ic
 fu
nc
tio
n
A
ge
 ad
ju
ste
d 
↑ in insu
lin
 le
ve
ls 
am
on
g 
am
pu
te
es
 v
s c
on
tro
ls;
 N
o 
un
ad
ju
ste
d 
di
¬e
re
nc
e i
n 
gl
uc
os
e, 
lip
id
s a
nd
 b
lo
od
 
pr
es
su
re
53
 n
on
m
ili
ta
ry
  
co
nt
ro
ls
5International Journal of Vascular Medicine
Ta
bl
e 
1:
 C
on
tin
ue
d.
Au
th
or
 y
ea
r
Po
pu
la
tio
n
N
um
be
rs
 an
d 
ty
pe
 o
f 
ex
po
su
re
St
ud
y 
de
sig
n
A
ge
 in
 y
ea
rs
M
al
e, 
%
 in
 
co
m
ba
t g
ro
up
Fo
llo
w
 
up
O
ut
co
m
es
Ke
y 
£n
di
ng
/c
ov
ar
ia
te
 ad
ju
stm
en
t
M
od
an
 et
 al
. 
19
98
 [1
9]
Is
ra
eli
 ar
m
y 
 
w
ou
nd
ed
  
19
48
–1
97
4
C
oh
or
t 1
  
20
1v
et
er
an
s +
 tr
au
m
at
ic
 
lo
w
er
 li
m
b 
 
am
pu
ta
tio
n 
 
18
32
 g
en
er
al
 U
S 
po
pu
la
tio
n
Re
tro
sp
ec
tiv
e 
co
ho
rt
 st
ud
y
50
%
 <
40
 y
ea
rs
10
0%
24
-y
ea
r
A
ll-
ca
us
e C
V
D
 
an
d 
no
n 
CV
D
 
m
or
ta
lit
y
Tw
o 
fo
ld
 ↑ (ampu
te
es
 v
s. 
co
nt
ro
ls)
 in
  
un
ad
ju
ste
d 
ris
k 
of
 al
l-c
au
se
 (2
1.
9%
 
vs
. 1
2.
1%
  푝
<
0.0
01
 am
on
g 
ol
de
r)
 
an
d 
CV
D
-r
el
at
ed
 d
ea
th
 (8
.9
%
 v
s. 
3.
8%
,푝
<
0.0
01
)
C
oh
or
t 2
  
10
1 
am
pu
te
es
  
96
 co
nt
ro
ls 
(m
at
ch
ed
 b
y 
ag
e a
nd
 et
hn
ic
ity
)
Cr
os
s-
se
ct
io
na
l
CV
 ri
sk
 fa
ct
or
s
C
oh
or
t 2
 ↑ plasm
a i
ns
ul
in
 le
ve
ls 
(2
 h
ou
r-
po
st 
or
al
 g
lu
co
se
 lo
ad
) i
n 
am
pu
te
es
; N
o 
di
¬e
re
nc
es
 in
 u
na
dj
us
te
d 
CH
D
 (1
9.
8%
 
vs
. 1
6.
7%
), 
ce
re
br
ov
as
cu
la
r d
ise
as
e (
3.
0%
 
vs
. 5
.2
%
), 
ob
es
ity
, D
M
, H
TN
 (4
3.
6%
 v
s. 
35
.4
%
), 
hy
pe
rli
pi
de
m
ia
 (3
7.
6%
 v
s. 
30
.2
%
)
Sh
ah
ria
r e
t a
l. 
20
09
 [3
7]
Ir
an
ia
n 
w
ar
s
32
7 
bi
la
te
ra
l l
ow
er
 li
m
b 
am
pu
te
es
Cr
os
s-
se
ct
io
na
l
42
 y
ea
rs
 at
 an
al
ys
is 
w
ith
 
ag
e o
f 2
0.
6 
ye
ar
s a
t i
nj
ur
y 
co
nt
ro
l g
ro
up
 ag
e n
ot
 
re
po
rt
ed
10
0%
M
ea
n 
22
.3
O
be
sit
y 
an
d 
CV
D
 ri
sk
 fa
ct
or
s
↑ unadju
ste
d 
ris
k 
of
 H
TN
 (2
8.
5%
 v
s. 
20
.4
%
: 푝
<
0.0
5)
, t
ot
al
 an
d 
LD
L 
 
ch
ol
es
te
ro
l (
푃
<
0.0
5)
 o
be
sit
y 
(3
1.
8%
 v
s. 
22
.3
%
) a
nd
 sm
ok
in
g 
(3
1.
8%
 v
s. 
22
.3
%
; 
푝
<
0.0
5)
 v
er
su
s c
on
tro
l
Ir
an
ia
n 
ge
ne
ra
l  
po
pu
la
tio
n 
(d
em
og
ra
ph
ic
s 
un
de
£n
ed
) r
ef
er
en
ce
 [5
]
Ku
nn
as
 et
 al
. 
20
11
 [2
4]
Fi
nn
ish
 M
ili
ta
ry
 
W
W
II
 v
et
er
an
s
10
2 
in
ju
re
d 
co
m
ba
t v
et
-
er
an
s
Pr
os
pe
ct
iv
e 
co
ho
rt
 st
ud
y
55
 y
ea
rs
10
0%
28
 y
ea
rs
CH
D
 m
or
ta
lit
y
(↑ adjust
ed
 ri
sk
 o
f C
H
D
 (H
R 
1.
7 :
 1.
1–
2.
5;
 
푝
=
0.0
2)
 d
ea
th
 am
on
g 
in
ju
re
d/
w
ou
nd
ed
 
vs
 co
nt
ro
l. 
N
o 
di
¬e
re
nc
e i
n 
to
ta
l  
ch
ol
es
te
ro
l o
r D
M
56
5 
no
n 
in
ju
re
d 
ve
te
ra
ns
St
ew
ar
t e
t a
l. 
20
15
 [2
7]
U
S 
M
ili
ta
ry
 Ir
aq
 
an
d 
A
fg
ha
ni
sta
n 
w
ar
s 2
00
2–
20
11
38
46
 se
ve
re
 tr
au
m
at
ic
 
in
ju
rie
s
Re
tro
sp
ec
tiv
e 
co
ho
rt
25
–2
9.
2 
ye
ar
s
≥9
8%
1.
1–
4.
3 
ye
ar
s
A
rm
ed
 F
or
ce
s 
M
ed
ic
al
  
Ex
am
in
er
  
Sy
ste
m
 
(A
FM
ES
) d
at
a-
ba
se
 o
f o
ut
co
m
es
Ea
ch
 5
-p
oi
nt
 ↑in the 
IS
S 
lin
ke
d 
to
 a 
6%
, 
13
%
 an
d 
13
%
 ↑ in the
 ad
ju
ste
d 
ris
k 
of
 
H
TN
 (O
R 
1.
06
; 1
.0
2–
1.
09
; 푃
=
0.0
03
), 
CA
D
 (1
.1
3;
 9
5%
 C
I 1
.0
3–
1.
25
; 푃
=
0.0
1),
 
D
M
 (1
.1
3;
 1
.0
4–
1.
23
; 푃
=
0.0
03
). 
↑ Risk 
ve
rs
us
 co
nt
ro
l p
op
ul
at
io
n
M
ill
en
ni
um
 co
ho
rt
 [3
0,
 4
1]
Ej
ta
he
d 
et
 
al
.2
01
7 
[4
6]
Ir
an
 v
et
er
an
s o
f 
Ir
an
-I
ra
q 
W
ar
23
5 
ve
te
ra
ns
 w
ith
  
bi
la
te
ra
l t
ra
um
at
ic
  
lo
w
er
 li
m
b 
am
pu
ta
tio
ns
 v
s 
ge
ne
ra
l p
op
ul
at
io
n
Cr
os
s-
se
ct
io
na
l
31
.5
 y
ea
rs
 at
 in
ju
ry
 an
d 
52
 y
ea
rs
 at
 fo
llo
w
 u
p
10
0%
32
.1
 
ye
ar
s 
fo
rm
 
in
ju
ry
M
et
ab
ol
ic
 sy
n-
dr
om
e
2-
fo
ld
 ↑ in me
ta
bo
lic
 sy
nd
ro
m
e, 
 
in
clu
di
ng
 H
TN
, i
ns
ul
in
 le
ve
ls,
  
hy
pe
rli
pi
de
m
ia
 an
d 
ob
es
ity
 (a
m
pu
te
es
 
(6
2.
1%
) v
s g
en
er
al
 Ir
an
ia
n 
po
pu
la
tio
n 
(2
7.
5%
 )
A
ge
 fo
r c
om
pa
ra
to
r n
ot
 
re
po
rt
ed
Un
in
ju
re
d 
co
m
ba
t‡
Bu
llm
an
 et
 al
. 
19
90
 [2
0]
U
S 
Vi
et
na
m
 W
ar
 
ve
te
ra
ns
66
68
 h
ig
h-
co
m
ba
t v
et
er
an
s 
de
at
hs
Re
tro
sp
ec
tiv
e 
co
ho
rt
Si
m
ila
r a
ge
s i
n 
bo
th
 
gr
ou
ps
10
0%
M
ed
ia
n 
fo
llo
w
 
up
 >
5 
ye
ar
s
IC
D
8 
8 
co
de
s
↓ in prop
or
tio
na
te
 C
V
D
 m
or
ta
lit
y 
vs
  
co
nt
ro
l g
ro
up
 (m
or
ta
lit
y 
 
ra
tio
 0
.9
3 :
 0.
88
–0
.9
8)
.
27
91
7 
lo
w
 co
m
ba
t v
et
er
an
 
de
at
hs
International Journal of Vascular Medicine6
Ta
bl
e 
1:
 C
on
tin
ue
d.
Au
th
or
 y
ea
r
Po
pu
la
tio
n
N
um
be
rs
 an
d 
ty
pe
 o
f 
ex
po
su
re
St
ud
y 
de
sig
n
A
ge
 in
 y
ea
rs
M
al
e, 
%
 in
 
co
m
ba
t g
ro
up
Fo
llo
w
 
up
O
ut
co
m
es
Ke
y 
£n
di
ng
/c
ov
ar
ia
te
 ad
ju
stm
en
t
O
’T
oo
le
 et
 al
. 
19
96
 [4
0]
Au
str
al
ia
n 
Vi
et
na
m
 
W
ar
 v
et
er
an
s
64
1 
ar
m
y 
ve
te
ra
ns
 (1
0.
8%
 
in
ju
re
d)
 v
s  
ag
e-
se
x 
m
at
ch
ed
  
po
pu
la
tio
n 
ex
pe
ct
ed
Cr
os
s-
se
ct
io
na
l
29
.5
 y
ea
rs
 at
 m
ili
ta
ry
 
di
sc
ha
rg
e
10
0%
>1
5 
ye
ar
s
Se
lf-
re
po
rt
ed
 
ph
ys
ic
al
 h
ea
lth
 
sta
tu
s
↑ adjuste
d 
ris
k 
of
 H
TN
 (R
R 
2.
17
 :  
1.
71
–2
.6
2)
, D
M
 (2
.7
1 :
 1.
32
–4
.0
9)
 an
d 
lip
id
s (
2.
73
 : 1
.9
4–
3.
52
); 
CV
D
 (R
R 
1.
98
 : 
 0.
52
–2
.3
3)
 n
ot
 si
gn
i£
ca
nt
. N
o 
re
la
tio
n-
sh
ip
 b
et
w
ee
n 
in
cr
ea
sin
g 
co
m
ba
t b
ur
de
n 
to
 an
y 
CV
D
 o
ut
co
m
es
 o
r r
isk
 fa
ct
or
s
M
ac
Fa
rla
ne
  
et
 al
. 2
00
0 
[2
1]
U
K 
M
ili
ta
ry
  
ve
te
ra
ns
 o
f G
ul
f 
W
ar
 I 
(1
99
0–
91
)
53
41
6 
w
ar
 v
et
er
an
s
Re
tro
sp
ec
tiv
e 
co
ho
rt
71
.5
%
 <
30
 y
ea
rs
 at
 st
ud
y 
en
ro
lm
en
t
97
.7
%
8 
ye
ar
s
M
ul
tip
le
N
o 
sig
ni
£c
an
t d
i¬
er
en
ce
 in
 al
l-c
au
se
 
(M
RR
 1
.0
5 :
 0.
91
–1
.2
1)
 an
d 
CV
D
 m
or
ta
lit
y 
(0
.7
4 :
 0.
49
–1
.1
2)
 am
on
g 
de
pl
oy
ed
 v
s  
no
nd
ep
lo
ye
d 
ve
te
ra
ns
 m
or
ta
lit
y
53
45
0 
no
nd
ep
lo
ye
d 
m
il-
ita
ry
Ei
se
n 
et
 al
.  
20
05
 [4
2]
U
S 
M
ili
ta
ry
 G
ul
f 
W
ar
 (1
99
1)
10
61
de
pl
oy
ed
 w
ar
 v
et
er
an
s
Cr
os
s-
se
ct
io
na
l
30
.9
 y
ea
rs
 d
ep
lo
ye
d
78
%
 in
 b
ot
h 
gr
ou
ps
10
 y
ea
rs
Ph
ys
ic
al
 h
ea
lth
 
an
d 
Q
O
L
N
o 
sig
ni
£c
an
t d
i¬
er
en
ce
 in
 ad
ju
ste
d 
ris
k 
of
 D
M
 (1
.5
2 :
 0.
81
–2
.8
5)
 o
r h
yp
er
te
ns
io
n 
(0
.9
0 :
 0.
60
–1
.3
3)
11
28
 n
on
de
pl
oy
ed
32
.6
 y
ea
rs
 n
on
 d
ep
lo
ye
d∗
G
ra
na
do
 et
 al
. 
20
09
 [4
1]
U
S 
M
ili
ta
ry
 (2
00
1–
20
03
) (
25
%
 Ir
aq
 an
d 
A
fg
ha
ni
sta
n)
43
85
 co
m
ba
t
Pr
os
pe
ct
iv
e 
co
ho
rt
N
ot
 re
po
rt
ed
74
.8
–8
6%
2.
7 
ye
ar
s
SF
-3
6 
 
qu
es
tio
nn
ai
re
 
ar
te
ria
l  
hy
pe
rt
en
sio
n
↑ adjuste
d 
in
ci
de
nc
e o
f H
TN
 am
on
g 
 
m
ul
tip
le
 co
m
ba
t v
et
er
an
s v
s. 
no
nd
ep
lo
y-
er
s (
O
R 
1.
33
 : 1
.0
7–
1.
65
:푝
<
0.0
5)
44
44
 d
ep
lo
ye
d 
 
no
nc
om
ba
t
Bu
t g
ro
up
ed
 b
y 
bi
rt
h∗
 
de
ca
de
s
27
23
2 
no
nd
ep
lo
ye
d
Ka
ng
 et
 al
.  
20
09
 [2
8]
U
S 
G
ul
f W
ar
 (1
99
1)
 
ve
te
ra
ns
61
11
 w
ar
 v
et
er
an
s
Cr
os
s-
se
ct
io
na
l 
an
al
ys
is 
of
  
pr
os
pe
ct
iv
e 
co
ho
rt
31
.5
 y
ea
rs
 fo
r w
ar
 v
et
-
er
an
s
79
.9
%
 ac
tiv
e 
78
.2
%
 co
nt
ro
l1
4 
ye
ar
s
H
ea
lth
  
qu
es
tio
n 
na
ire
s
↑ adjuste
d 
se
lf-
re
po
rt
ed
 p
re
va
le
nc
e o
f 
H
TN
 (R
R 
1.
11
 : 1
.0
4–
1.
19
), 
str
ok
e (
RR
 
1.
32
 : 1
.1
4–
1.
52
), 
CH
D
 (R
R 
1.
22
 :  
1.
08
–1
.3
9)
 an
d 
ob
es
ity
. N
o 
sig
ni
£c
an
t 
di
¬e
re
nc
e i
n 
D
M
 (R
R 
1.
11
 : 0
.9
9–
1.
25
)
38
59
 v
et
er
an
s n
ot
  
de
pl
oy
ed
 to
 P
er
sia
n 
G
ul
f
33
.6
 y
ea
rs
 fo
r c
on
tro
l  
(in
 1
99
1)
∗
Jo
hn
so
n 
et
 al
. 
20
10
 [3
3]
U
S 
Ve
te
ra
ns
 W
or
ld
 
W
ar
 II
 4
0.
6%
 (1
94
1–
19
45
), 
Ko
re
an
 W
ar
 
34
.6
%
 (1
95
0–
19
53
) 
Vi
et
na
m
 C
on
¸i
ct
 
16
.8
%
 (1
96
1–
19
75
)
11
78
 co
m
ba
t (
13
.1
%
 v
et
er
-
an
s)
 2
12
7 
 
no
nc
om
ba
t (
de
pl
oy
ed
) 
ve
te
ra
ns
Pr
os
pe
ct
iv
e 
co
ho
rt
19
–2
0 
ye
ar
s a
t e
nr
ol
m
en
t
10
0%
36
 y
ea
rs
 
a°
er
 
m
ili
ta
ry
 
en
tr
y
Ca
ro
tid
  
in
tim
a-
m
ed
ia
  
th
ic
kn
es
s 
(C
IM
T)
 an
d 
ca
ro
tid
 p
la
qu
e
↑ age-ad
ju
ste
d 
CI
M
T 
in
 co
m
ba
t v
et
er
an
s 
(R
isk
 d
i¬
er
en
ce
 1
2.
79
 µm
 : 0
.7
2–
24
.8
6)
  
no
nc
om
ba
t v
et
er
an
s. 
N
o 
sig
ni
£c
an
t  
di
¬e
re
nc
e i
n 
ca
ro
tid
 p
la
qu
e n
ot
ed
57
.3
 y
ea
rs
 co
m
ba
t 
ve
te
ra
ns
2,
04
2 
no
nm
ili
ta
ry
51
.8
 y
ea
rs
 n
on
 v
et
er
an
s
54
.1
 y
ea
rs
 n
on
-c
om
ba
t 
ve
te
ra
ns
∗
Jo
hn
so
n 
et
 al
. 
20
10
 [4
4]
U
S 
Ve
te
ra
ns
 W
or
ld
 
W
ar
 II
 4
0.
6%
 (1
94
1–
19
45
), 
Ko
re
an
 W
ar
 
34
.6
%
 (1
95
0–
19
53
) 
Vi
et
na
m
 C
on
¸i
ct
 
16
.8
%
 (1
96
1–
19
75
)
11
78
 co
m
ba
t v
et
er
an
s 
(1
3.
1%
 in
ju
re
d)
Pr
os
pe
ct
iv
e 
co
ho
rt
19
–2
0 
ye
ar
s a
t e
nr
ol
m
en
t
10
0%
36
 y
ea
rs
 
a°
er
 
m
ili
ta
ry
 
en
tr
y
M
yo
ca
rd
ia
l 
in
fa
rc
tio
n 
 
un
sta
bl
e  
an
gi
na
 o
r 
CH
D
-r
el
at
ed
 
de
at
h
N
o 
sig
ni
£c
an
t d
i¬
er
en
ce
s i
n 
ad
ju
ste
d 
CH
D
 b
et
w
ee
n 
co
m
ba
t (
13
.2
%
) a
nd
  
no
nc
om
ba
t v
et
er
an
s (
11
.3
%
), 
an
d 
no
nv
et
-
er
an
s (
11
.6
%
); 
sim
ila
r i
sc
ha
em
ic
 st
ro
ke
 
ris
k 
(7
.7
6%
 v
s. 
5.
22
%
 v
s. 
6.
43
%
). 
 
↑ preval
en
ce
 o
f D
M
 co
m
ba
t v
s n
on
co
m
-
ba
t b
ut
 n
o 
sig
ni
£c
an
t d
i¬
er
en
ce
 in
 H
TN
, 
lip
id
 p
ro
£l
es
57
.3
 co
m
ba
t v
et
er
an
s
21
27
 n
on
co
m
ba
t  
(d
ep
lo
ye
d)
 v
et
er
an
s
51
.8
 n
on
 v
et
er
an
s
2,
04
2 
no
nm
ili
ta
ry
54
.1
 n
on
-c
om
ba
t 
ve
te
ra
ns
∗
7International Journal of Vascular Medicine
Ta
bl
e 
1:
 C
on
tin
ue
d.
Au
th
or
 y
ea
r
Po
pu
la
tio
n
N
um
be
rs
 an
d 
ty
pe
 o
f 
ex
po
su
re
St
ud
y 
de
sig
n
A
ge
 in
 y
ea
rs
M
al
e, 
%
 in
 
co
m
ba
t g
ro
up
Fo
llo
w
 
up
O
ut
co
m
es
Ke
y 
£n
di
ng
/c
ov
ar
ia
te
 ad
ju
stm
en
t
Cr
um
-
Ci
an
¸o
ne
 et
 al
. 
20
14
 [3
0]
U
S 
M
ili
ta
ry
 Ir
aq
 
an
d 
A
fg
ha
ni
sta
n 
w
ar
s 2
00
1–
20
09
12
28
0 
de
pl
oy
ed
 co
m
ba
t
Pr
os
pe
ct
iv
e 
co
ho
rt
34
.4
 y
ea
rs
 at
 b
as
eli
ne
  
an
d 
m
ea
n 
ag
e a
t C
H
D
 
di
ag
no
sis
 4
3.
1 
ye
ar
s  
(c
om
pa
ra
tiv
e a
ge
s n
ot
 
re
po
rt
ed
)
84
.4
%
5.
6 
ye
ar
s
C
or
on
ar
y 
 
he
ar
t d
ise
as
e
C
om
ba
ta
nt
s ↑ adjus
te
d 
(a
ge
, s
ex
, r
ac
e)
 
ris
k 
of
 C
H
D
 (O
R 
1.
63
 : 1
.1
1–
2.
40
) v
s 
de
pl
oy
ed
 n
on
co
m
ba
t s
er
vi
ce
m
en
 b
ut
 ↓ 
un
ad
ju
ste
d 
ris
k 
of
 D
M
 an
d 
hy
pe
rt
en
sio
n
10
60
2 
de
pl
oy
ed
  
no
nc
om
ba
t
37
14
3 
no
nd
ep
lo
ye
d 
m
il-
ita
ry
Sc
hl
en
ge
r e
t a
l. 
20
15
 [2
2]
U
S 
Vi
et
na
m
 W
ar
 
ve
te
ra
ns
16
32
 th
ea
tre
 v
et
er
an
s
Re
tro
sp
ec
tiv
e 
co
ho
rt
41
.5
 y
ea
rs
 th
ea
tre
 v
et
-
er
an
s
>9
5%
>1
0 
ye
ar
s
IC
D
 co
de
s  
fo
r c
au
se
s o
f  
de
at
h
N
o 
sig
ni
£c
an
t d
i¬
er
en
ce
 in
 al
l c
au
se
 
(1
6.
79
%
 v
s. 
16
.6
1%
), 
CV
D
 (5
.2
3%
 v
s. 
3.
81
%
) o
r C
H
D
-r
el
at
ed
 (3
.0
2%
 v
s. 
2.
33
%
) 
de
at
hs
71
6 
Er
a (
no
nc
om
ba
t) 
ve
te
r-
an
 co
nt
ro
ls
40
.9
 y
ea
rs
 co
nt
ro
l
Ba
rt
h 
et
 al
. 
20
16
 [2
3]
U
K 
G
ul
f W
ar
 (1
99
1)
62
19
01
 G
ul
f W
ar
  
ve
te
ra
ns
  
74
62
47
 n
on
co
m
ba
t v
et
er
an
s
Re
tro
sp
ec
tiv
e 
C
oh
or
t
28
 y
ea
rs
 –
 w
ar
 v
et
er
an
s
93
%
 ac
tiv
e
13
.6
 
ye
ar
s
A
ll 
ca
us
e a
nd
 
di
se
as
e  
sp
ec
i£
c  
m
or
ta
lit
y 
 
(I
CD
-9
)
N
o 
di
¬e
re
nc
e i
n 
ad
ju
ste
d 
CV
D
 m
or
ta
lit
y 
am
on
g 
G
ul
f W
ar
 v
s n
on
co
m
ba
t v
et
er
an
s 
(0
.9
9 :
 0.
09
3–
1.
05
) b
ut
 ↓ all-cau
se
 m
or
ta
l-
ity
 (R
R 
0.
97
 : 0
.9
5%
–0
.9
9%
). 
↓ risk of
 al
l 
ca
us
e (
RR
 0
.4
9 :
 0.
48
–0
.5
0)
 an
d 
CV
D
 (R
R 
0.
43
 : 0
.4
2–
0.
45
) r
el
at
ed
 m
or
ta
lit
y 
in
 G
ul
f 
W
ar
 v
et
er
an
s v
s. 
U
S 
po
pu
la
tio
n
30
 y
ea
rs
 –
 n
on
co
m
ba
t 
ve
te
ra
ns
∗
86
.7
%
 co
n-
tro
l∗
U
S 
ge
ne
ra
l p
op
ul
at
io
n
Si
gn
i£
ca
nt
Sh
eÂ
er
 et
 al
. 
20
16
 [3
2]
U
S 
Vi
et
na
m
 W
ar
 
ve
te
ra
ns
 1
95
9–
19
73
10
7 
co
m
ba
t v
et
er
an
s 6
20
 
no
nc
om
ba
t c
on
tro
ls
Cr
os
s-
se
ct
io
na
l
45
.4
 y
ea
rs
 –
 co
m
ba
t
10
0%
10
 y
ea
rs
M
ul
tip
le
 h
ea
lth
 
ou
tc
om
es
↓ adjuste
d 
(O
R 
0.
25
 : 0
.0
9–
0.
63
; 푝
=
0.0
03
) 
ra
te
 o
f d
ia
be
te
s a
m
on
g 
no
nc
om
ba
t  
se
rv
ic
em
en
. N
o 
di
¬e
re
nc
e i
n 
un
ad
ju
ste
d 
CH
D
, h
yp
er
te
ns
io
n,
 h
ea
rt
 at
ta
ck
s o
r 
str
ok
e
46
.0
 y
ea
rs
 –
 n
on
co
m
ba
t

om
as
 et
 al
. 
20
17
 [3
1]
U
S 
M
ili
ta
ry
 v
et
er
-
an
s V
ie
tn
am
 w
ar
 
(4
3.
6%
)
56
4 
co
m
ba
t v
et
er
an
s 
(2
9.
2%
 in
ju
re
d)
Cr
os
s-
se
ct
io
na
l
59
.0
 y
ea
rs
 –
 co
m
ba
t
87
.6
–9
3%
>2
0 
ye
ar
s
Va
lid
at
ed
 h
ea
lth
  
qu
es
tio
nn
ai
re
s
↑ adjuste
d 
ris
k 
of
 st
ro
ke
 (O
R 
1.
38
 :  
1.
03
–3
.3
3)
; n
o 
di
¬e
re
nc
e i
n 
ad
ju
ste
d 
ris
k 
of
 h
ea
rt
 at
ta
ck
s, 
hi
gh
 ch
ol
es
te
ro
l H
TN
 
an
d 
ot
he
r h
ea
rt
 d
ise
as
e
61
.3
 y
ea
rs
 –
 n
on
co
m
ba
t∗
91
6 
no
nc
om
ba
t v
et
er
an
s
H
in
oj
os
a 2
01
8 
[2
9]
U
S 
M
ili
ta
ry
 Ir
aq
 
an
d 
A
fg
ha
ni
sta
n 
W
ar
s 2
01
2–
20
15
14
93
2 
co
m
ba
t v
et
er
an
s 
13
51
35
 ci
vi
lia
ns
Cr
os
s-
se
ct
io
na
l
56
.1
 y
ea
rs
 –
 v
et
er
an
s  
48
.8
 y
ea
rs
 –
 co
nt
ro
l∗
66
.3
%
 in
 m
il-
ita
ry
 g
ro
up
 
vs
 4
2%
 in
 
no
nm
ili
ta
ry
 
co
nt
ro
ls∗
>1
 y
ea
r
CV
D
  
ou
tc
om
es
↑ adjuste
d 
pr
ev
al
en
ce
 o
f H
TN
 in
 v
et
er
an
s 
(O
R 
1.
49
 : 1
.2
3–
1.
81
), 
CH
D
 (O
R 
1.
55
 :  
1.
0–
2.
40
), 
an
d 
he
ar
t a
tta
ck
s (
2.
26
 :  
1.
41
–3
.6
2)
; ↑ rates 
of
 st
ro
ke
 am
on
g 
m
al
e 
on
ly
 v
et
er
an
s (
O
R 
3.
32
 : 2
.0
3–
5.
47
)
CH
D
, c
or
on
ar
y 
he
ar
t d
ise
as
e; 
D
M
, d
ia
be
te
s m
el
lit
us
; C
V
D
, c
ar
di
ov
as
cu
la
r d
ise
as
e; 
H
TN
, h
yp
er
te
ns
io
n,
 R
es
ul
ts 
pr
es
en
te
d 
in
 b
ra
ck
et
s a
s o
dd
s r
at
io
, r
el
at
iv
e 
ris
k 
an
d 
95
%
 c
on
£d
en
ce
 in
te
rv
al
s u
nl
es
s s
ta
te
d;
 C
H
D
, 
co
ro
na
ry
 h
ea
rt
 d
ise
as
e; 
D
M
, d
ia
be
te
s m
el
lit
us
; C
V
D
 c
ar
di
ov
as
cu
la
r d
ise
as
e; 
H
TN
, h
yp
er
te
ns
io
n;
 A
KA
, a
bo
ve
 k
ne
e 
am
pu
ta
tio
n;
 IS
S,
 in
ju
ry
 se
ve
rit
y 
Sc
or
e. 
Re
su
lts
 p
re
se
nt
ed
 in
 b
ra
ck
et
s a
s o
dd
s r
at
io
 (O
R)
, r
el
at
iv
e 
ris
k 
(R
R)
, m
or
ta
lit
y 
ra
te
 ra
tio
 (M
RR
), 
ha
za
rd
 ra
tio
 (H
R)
 a
nd
 9
5%
 c
on
£d
en
ce
 in
te
rv
al
s u
nl
es
s s
ta
te
d;
 ‡
re
fe
rs
 to
 st
ud
ie
s w
he
re
 p
ro
po
rt
io
n 
w
ith
 tr
au
m
at
ic
 in
ju
ry
 <
50
%
. ✳
D
et
ai
le
d 
de
m
og
ra
ph
ic
s f
or
 th
is 
po
pu
la
tio
n 
ei
th
er
 n
ot
 fu
lly
 d
e£
ne
d 
or
 d
isc
lo
se
d.
International Journal of Vascular Medicine8
푝 = 0.77: 푝 < 0.0001) (Figure 3). In the only cohort study of 
combat versus no combat (without signi£cant TI) Schlenger 
(moderate ROB) did not observe a signi£cant di¬erence in 
CHD-related (3.02% vs. 2.33%) deaths among US Vietnam 
combat versus noncombat veterans [22].
3.5. Myocardial Infarction and CHD. e risk of CHD or 
myocardial infarction was reported in ten studies (Tables 
1 and 2). Four studies (two cohort and two cross sectional) 
reported outcome data following TI; two reported an increased 
risk [9, 24], whilst two were neutral [19, 25]. In the £rst of 
the two studies reporting an increased risk, Yekutiel and 
colleagues observed a higher risk of CHD among 53 lower 
limb amputees wounded from 1948 to 1973 versus 159 age-
matched healthy controls [26]. In the second study, Stewart 
and colleagues reported a signi£cantly higher risk of CHD 
risk among combatants surviving very serious TI versus the 
age-matched general population [27]. Furthermore, each £ve-
point increase in the Injury Severity Score was linked to a 13% 
increase in the adjusted risk of CHD (Hazard ratio 1.13; 95% 
CI, 1.03–1.25; 푝 = 0.01) [27]. ere were six studies (one cohort 
and £ve cross sectional) that reported on CHD risk following 
combat exposure without TI. An increased risk with combat 
was observed in three studies (two low and one moderate ROB) 
[28–30], with no signi£cant di¬erence noted in another three 
(one low, one moderate and one high ROB) [31–33].
3.6. Stroke. Seven studies reported stroke outcomes (Tables 1 
and 2), but these were predominantly cross sectional studies 
and possessed a signi£cant ROB. In the only cohort study 
of combatants following TI (moderate ROB) there was no 
reported di¬erence in stroke rates between veterans with 
and without proximal amputation (three versus two strokes, 
respectively) [19]. Among the population with combat 
exposure without TI £ve studies were identi£ed; three of 
these studies reported an increased risk with combat versus 
non-combat controls (all cross sectional; one with low ROB, 
one moderate, one high) [28, 29, 31]. Two of the £ve studies 
reported no di¬erence in risk (one cross sectional and one 
cohort; one low ROB and one moderate) [32, 33].
3.7. Aortic Aneurysm. Two cross sectional studies reported the 
risk of aortic aneurysms following TI. In one study, Vollmar et 
al. observed a higher prevalence of infrarenal aortic aneurysms 
(5.8% vs 1.1%) among veterans (푛 = 329) with above knee 
amputations, compared to deployed veterans without (푛 = 702) 
(high ROB) [34]. In the second study, there was no di¬erence 
(4.4% vs. 4.0%) in ultrasound detected aortic aneurysms 
among veterans with lower limb amputation versus a control 
population of similar age (high ROB) [25].
3.8. Hypertension. 19 studies reported the risk of hypertension 
(Tables 1 and 2). ere were ten studies (eight cross sectional 
and two cohort) relating to TI. e risk of hypertension, 
was reported to be increased in £ve studies (one moderate 
and four high ROB) [27, 35–38], with another £ve studies 
reporting no in¸uence of TI (one moderate and four high 
ROB) in systolic hypertension [19, 25, 26, 34, 39]. ere were 
nine studies of combatants without TI (three cohort and six 
covered a total of eight major combat operations: World 
War I (1918) and II (1939–45), e Korean War (1950–53), 
Vietnam War (1961–1975), the Iran-Iraq Wars (1980–1988), 
Israeli Con¸icts (1948–1974), Gulf War I (1991) and the recent 
US/UK operations in Iraq and Afghanistan (2003–2014). 
Twelve studies comprised of participants with combat-related 
TI, whilst 14 studies included combat veterans without a 
signi£cant burden of TI (predominantly noninjured).
e age ranges at the time of study enrolment ranged from 
18 to 89 years. e study populations were predominantly 
male (range 78–100%). e majority of participants were, 
where stated, Caucasian (62.4–100%), with the vast majority 
(≥74% of stated) being of nono¦cer rank at the time of combat 
(±TI).
3.2. Study Quality and Risk of Bias. e quality scores for 
the 26 studies ranged from 6 to 19 (out of maximum of 20; 
see Supplementary Table 2). e mean quality score for all 
studies was 12.6 ± 3.1. Five studies were considered high 
quality (scores >15), 16 moderate quality [10–15] and £ve 
low quality (<10) (see Supplementary Table 2). e risk of 
bias was considered signi£cant in 19/26 studies (73.1%) (see 
Supplementary Table 3).
3.3. Cardiovascular Mortality. e outcome of cardiovascular 
death (Tables 1 and 2) was reported in six cohort studies. 
Hrubec and Ryder [9] observed an increased risk of adjusted 
all-cause (low ROB; RR:1.36: 95% Con£dence Interval (CI) 
1.25–1.48), CVD (RR:1.58: CI 1.40–1.79) and CHD-related 
death (RR:1.56: CI 1.36–1.79) among proximal amputees at/
above knee or elbow) vs. injured (wound or fractures without 
amputation) controls in their retrospective analysis of a ≥30 
year follow-up of injured World War II veterans [9]. Modan 
(moderate ROB) reported a two-fold higher CVD mortality 
risk following a 24 year follow-up of 201 wounded Israeli 
veterans with unilateral lower limb amputations compared 
with a sample (푛 = 1832) of the general US population 
of similar age [19]. e pooled data (Figure 2) from these 
two studies demonstrated a signi£cantly increased risk of 
cardiovascular related death (RR 1.80: 95% CI 1.24–2.62; 
퐼2 = 59%, 푝 = 0.002). Meta-analysis of the four studies (one 
low, one moderate and two high ROB) investigating the e¬ects 
of combat, without traumatic injury, identi£ed a marginal, yet 
signi£cantly lower pooled risk of cardiovascular death (hence 
no increase) in the active combat versus control population 
(RR 0.90: CI 0.83–0.98; 퐼2 = 47% , 푝 = 0.02) [20–23] (Figure 2).
3.4. Coronary Heart Disease (CHD) Mortality. CHD-related 
death was reported in only three studies (Tables 1 and 2). 
Hrubec and Ryder observed higher adjusted CHD related 
death (low ROB; RR 1.56: CI 1.36–1.79) amongst combat 
veterans with traumatic proximal amputations versus controls 
with dis£gurement injuries [9]. Kunnas et al. reported a higher 
adjusted risk of CHD (moderate ROB; RR 1.7: CI 1.1–2.5; 
푝 = 0.02) among injured combat veterans versus non-injured 
veterans from World War II con¸icts [24]. However, the nature 
and severity of the injuries were not de£ned. Pooled analysis 
con£rmed that TI was linked to an increased risk of CHD-
related mortality (risk ratio 1.57 : 95% CI 1.35–1.83; 퐼2 = 0%, 
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risk of diabetes compared with nonexposed controls (both 
low ROB) [30, 32].
3.9.2. Metabolic Syndrome. Only one cross sectional study 
reported metabolic syndrome as a speciﬁc outcome. Etjahed 
and colleagues observed a 2-fold higher risk of metabolic 
syndrome (Deﬁned according to the ATP III Criteria) [45] 
among 235 veterans with bilateral traumatic lower limb 
amputation versus controls from the general population (high 
ROB) [46].
3.9.3. Blood Lipid Levels. Comparative lipid levels and risk 
of hyperlipidaemia were reported in 11 studies. Among TI 
veterans two studies (cross sectional) reported an increased 
lipid proﬁle compared with controls (high ROB) [37, 46]. 
ere were six (two cohort and four cross sectional) studies 
that all reported no diﬀerence in lipid levels or risk of 
hyperlipidaemia among combatants with TI versus controls of 
TI (3 moderate and three high ROB) [19, 24–26, 34, 39]. ere 
were three studies of uninjured combat veterans (one cohort 
and two cross sectional); one study [40] reported a higher risk 
cross sectional), four of which found risk of hypertension to 
be higher following combat (two low, one moderate and one 
high ROB) [28, 29, 40, 41]; four studies found no eﬀect of 
combat (two low, one moderate and one high ROB) [31–33, 
42], whilst one study found combat was associated with a 
lower risk (moderate ROB) [30].
3.9. Cardiometabolic Risk Factors
3.9.1. Diabetes. e risk of diabetes was reported in 15 studies. 
Among the studies relating to combat TI, four studies (one 
cohort and three cross sectional) reported a signiﬁcantly 
higher risk associated with TI (one moderate and two high 
ROB) [26, 27, 37, 43] and four (two cohort and two cross 
sectional) reported no diﬀerence in risk between veterans with 
and without TI (two moderate and two high ROB) [19, 24, 25, 
34]. Among the studies of noninjured combatants, two (one 
cohort) reported an increased risk [40, 44], three (all cross 
sectional) no diﬀerence (two low and one high ROB) [28, 31, 
42] and two (one cohort and one cross sectional)found a lower 
Table 2: Relative outcomes investigated for included studies and their direction of ﬁndings.
Year
Cardio-
vascular 
mortality
CHD- 
mortality CHD/MI Stroke
Abdominal 
aortic aneu-
rysms
Carotid 
Intimal 
thickness
Diabetes 
mellitus HTN
Metabolic 
syndrome
Increased 
lipid proﬁle
Combat + Traumatic injury
Hrubec and Ryder [9] 1980 ↑ ↑ - - - - - - - -
Labouret et al. [35] 1983 - - - - - - - ↑ - -
Rose et al. [36] 1987 - - - - - - - ↑ - ↔
Vollmar et al. [34] 1989 - - - - ↑ - ↔ ↔ - ↔
Yekutiel et al. [26] 1989 - - ↑ - - - ↑ ↔ - -
Lorenz et al. [25] 1994 - - ↔ ↔ ↔ - ↔ ↔ - ↔
Peles et al. [43] 1995 - - - - - - ↑ ↔ - ↔
Modan et al. [19] 1998 ↑ ↔ ↔ - - ↔ ↔ - ↔
Kunnas et al. [24] 2011 - ↑ - - - - ↔ - - ↔
Shariar et al. [37] 2009 - - - - - - ↑ ↑ - ↑
Stewart et al. [27] 2015 - – ↑ - - - ↑ ↑ - -
Ejtahed et al. [46] 2017 - - - - - - - ↑ ↑ ↑
Combat only
Bullman et al. [20] 1990 ↓ - - - - - - - - -
O’Toole et al. [40] 1996 - - - - - - ↑ ↑ - ↑
MacFarlane et al. [21] 2000 ↔ - - - - - - - - -
Eisen et al. [42] 2005 - - - - - - ↔ ↔ - -
Granado et al. [41] 2009 - - ↑ - -
Kang et al. [28] 2009 - - ↑ ↑ - - ↔ ↑ - -
Johnson et al. [33] 2010 - - - - - ↑ - -
Johnson et al. [44] 2010 - - ↔ ↔ - - ↑ ↔ - ↔
Crum-Cianﬂone et al. [30] 2014 - - ↑ - - - ↓ ↓ - -
Schlenger et al. [22] 2015 ↔ ↔ - - - - - - - -
Barth et al. [23] 2016 ↔ - - - - - - - - -
Sheﬄer et al. [32] 2016 - - ↔ ↔ - - ↓ ↔ - -
omas et al. [31] 2017 - - ↔ ↑ - - ↔ ↔ - ↔
Hinojosa [29] 2018 - - ↑ ↑ - - - ↑ - -
CHD, coronary heart disease; MI, myocardial infarction; HTN, hypertension; Number refer to study ﬁndings in terms of direction of eﬀect in relation to com-
bat/injury versus control population: ↑, signiﬁcantly increased/positive; ↔, no signiﬁcant diﬀerence; ↓ lower risk; - unreported.
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risk. e SOE supporting of a link between combat-related TI 
and an increased risk of cardiovascular death and CHD-related 
death is low. ere is insu¦cient SOE linking combat-related 
TI (mainly lower limb amputations) to adverse cardiovascular 
outcome or risk factors. ere is also insu¦cient evidence 
that combat exposure, in the absence of signi£cant traumatic 
injury, is associated with an increase in adverse cardiovascular 
outcomes or cardiovascular risk.
4. Discussion
is is the £rst systematic review to examine the e¬ects of combat 
exposure and TI on CVD-related mortality, as well as a wide range 
of cardiovascular risk factors. ere is low SOE to support an 
association between combat-related TI and an increased risk of 
cardiovascular death and CHD-related mortality. ere is insuf-
£cient evidence to support an association between combat-re-
lated TI and increased cardiovascular risk. Furthermore, there is 
(moderate ROB) and two studies found no di¬erences in lipids 
levels of combatants versus controls (one moderate and one 
high ROB) [31, 44].
3.9.4. Other Cardiovascular Risk Factors. Only one study 
examined carotid intimal thickness (CIMT), a known 
surrogate for subclinical atherosclerosis, among non-
injured combat and noncombat veterans versus their civilian 
population [33]. CIMT was found to be higher among combat 
veterans (802.4 ± 182.2 휇m) compared with noncombat 
veterans (757.7 ± 164.1 휇m) even a°er adjustment for potential 
confounders (including age and race). However, there was 
no signi£cant di¬erence in carotid plaque burden a°er 
adjusting for confounders. ere were no identi£ed studies 
that examined the comparative measures of arterial sti¬ness 
or atrial £brillation with traumatic injury or military combat.
3.9.5. Strength of Evidence. Table 3 summarises the overall 
SOE relating to the e¬ects of combat ± TI upon cardiovascular 
Ecperimental Control Risk ratio Risk ratio
Study or subgroup
Events Total TotalEvents
Weight
M-H, Random, 95% M-H, Random, 95% CI
2.1.1 Traumatic injury (amputees)
Hrubec 1980 597 3887 378 3890 68.2% 1.58 [1.40, 1.78] 
Modan 1998 18 201 69 1832 31.8% 2.38 [1.45, 3.91]
Subtotal (95% CI) 4088 5722 100.0% 1.80 [1.24, 2.62]
Total events 615 447
Heterogeneity: τ2 = 0.05; χ2 = 2.45, df = 1 (p = 0.12); I2 = 59%
Heterogeneity: τ2 = 0.00; χ2 = 5.64, df = 3 (p = 0.13); I2 = 47%
Test for overall eect: Z = 3.09 (p = 0.002)
Test for overall eect: Z = 2.43 (p = 0.02)
2.1.2 Noninjured combat
Bullman 1990
McFarlance 2000
Schlenger 2015
Barth 2016
Subtotal (95% CI)
Total events
1141 6668 1228 6674 42.5% 0.93 [0.86, 1.00] 
0.75 [0.50, 1.13]
1.29 [0.85, 1.95]
0.87 [0.83, 0.92]
0.90[0.83, 0.98]
36 395 46 378 3.7%
81 1549 29 716 3.6%
1761 10869 2734 14716 50.2%
19481 22484 100.0%
3019 4037
Test for subground dierences: χ2 = 12.47, df = 1 (p = 0.0004), I2 = 92.0%.
0.2 0.5 1 2 5
Favors control Favors combat +/– injury
CI Year
1980
 1998
1990
 2000
 2015
 2016
Figure 2: Pooled analysis of studies for the outcome of cardiovascular death.
Study or subgroup
Combat + Trumatic injury Control Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CIEvents Total Events Total
Weight
Hrubec 1980
Kunnas 2011
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.08, df = 1 (p = 0.77); I2 = 0% 
Test for overall eect: Z = 5.94 (p < 0.00001)
346 3887 229 4013 86.3% 1.56 [1.33, 1.83]
1.66 [1.11, 2.49]
1.57 [1.35, 1.83]100.0%45783989
102 80 565 13.7%24
370 309
0.01 0.1 1 10 100
Favours combat + TI Favours (control)
Figure 3: Pooled analysis of studies for the outcome of coronary heart disease death.
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cardiovascular risk following traumatic amputation. ese 
included increased insulin resistance, psychological stress, 
high risk behaviour among exposed subjects and the eﬀects 
of abnormal blood ﬂow proximal to the amputation. Other 
risk factors remain largely speculative and further research 
with a need to examine the other types of combat related TI.
ese two previous reviews highlight the need for further, 
more contemporaneous data from studies of participants in 
more recent military conﬂicts. ere is also a need to more 
robustly examine clinical cardiovascular endpoints, such as 
cardiovascular death, and recognised cardiovascular risk fac-
tors. If traumatic amputation truly leads to an increased risk 
of CVD, then it would be expected that there would be a rel-
atively higher burden and prevalence of established cardio-
vascular risk factors. Our current analysis did not ﬁnd this to 
be the case. Based on the assimilated data within our 
meta-analysis, there is insuﬃcient evidence, at present, to sup-
port a link between severe combat related TI and the 
insuﬃcient evidence to support a link between combat exposure 
without trauma and adverse cardiovascular risk or outcomes.
A PubMed search identiﬁed one systematic review and 
one literature review relating to cardiovascular risk following 
traumatic amputation in the last 30 years [10, 11]. Robbins et 
al. [11] undertook a systematic review of combat and non-com-
bat related amputations on the outcomes of CVD (four stud-
ies) [9, 19, 36, 47]) and cardiometabolic risk (two studies) [43, 
48], as well as examining joint and phantom limb pain. Unlike 
our current review, their injured cohort included both civilian 
and military participants. e most recent single study 
included in their systematic review was published 17 years ago 
and a pooled analysis of objective clinical outcomes (CVD and 
CHD-related death) was not undertaken. Naschitz & Lenger 
[10] undertook a literature review that was also published 10 
years ago and the most recent study included was published 
>30 years ago [39]. ey suggested a number of potential aeti-
ological factors that may be implicated in an increased 
Table 3: Summary of key clinical outcomes and strength of evidence.
CTI, combat related traumatic injury; CHD, coronary heart disease; SOE, strength of evidence; ROB, risk of bias; RR relative risk; OR, odds ratio; Negative 
studies refer to signiﬁcantly lower risk of outcome vs control in active group.
Outcome Study design/number of studies Findings and direction Overall strength of evidence
Cardiovascular mortality
-CTI Cohort 2, x-sectional 0 2 Positive 0 Negative Moderate ROB; low SOE
-Combat only Cohort 4, x-sectional 0 3 Neutral; 1 Negative (lower risk in combat vs control) Moderate ROB; insuﬃcient SOE
CHD mortality
-CTI Cohort 2, x-sectional 0 2 Positive Moderate ROB; low SOE
-Combat only Cohort 1, x-sectional 0 1 Negative (lower risk in combat vs control) Moderate ROB; insuﬃcient SOE
CHD/Myocardial infarction
-CTI Cohort 1, x-sectional 3 2 Positive; 2 Neutral High ROB, insuﬃcient SOE
-Combat only Cohort 2, x-sectional 4 3 Positive: 3 Neutral High ROB, insuﬃcient SOE
Stroke
-CTI Cohort 1, x-sectional 1 2 Neutral High ROB, insuﬃcient SOE
-Combat only Cohort 1, x-sectional 4 3 Positive and 2 Neutral High ROB, insuﬃcient SOE
Aortic aneurysm
-Combat only Cohort 0, x sectional 2 2 Positive High ROB, insuﬃcient SOE
-CTI Cohort 0, x-sectional 0 No studies Insuﬃcient
Carotid intimal thickness (CIMT)
-CTI Cohort 0, x-sectional 0 No studies Insuﬃcient
-Combat only Cohort 1, x-sectional 0 1 x Positive; No blinding; No diﬀerence in carotid plaque Moderate ROB, insuﬃcient SOE
Diabetes mellitus
-CTI Cohort 2, x-sectional 6 4 Positive 4 Neutral High ROB, insuﬃcient SOE
-Combat only Cohort 2, x-sectional 5 2 Positive, 3 Neutral, 2 Negative High ROB, insuﬃcient: high ROB
Hypertension
-CTI Cohort 1, x-sectional 9 5 Positive; 5 Neutral High ROB, insuﬃcient SOE
-Combat only Cohort 3, x-sectional: 6 4 Positive, 4 Neutral, 1 Negative High ROB, insuﬃcient SOE
Metabolic syndrome x-sectional: 1 CTI: 1 x Neutral CTI: insuﬃcient
-CTI Cohort 0, x-sectional 1 1 Positive Very high ROB, insuﬃcient
-Combat only No studies Insuﬃcient
Hyperlipidaemia
-CTI Cohort 2, x-sectional 6 2 Positive, 6 Neutral (variable or unreported case deﬁnition) High ROB, insuﬃcient SOE
-Combat only Cohort 1, x-sectional 2 1 Positive, 2 Neutral High ROB, insuﬃcient SOE
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is a major concern, we failed to identify any unpublished 
studies (on reviewing the grey literature) that would support 
this concern. One considerable source of potential bias relates 
to the large heterogeneity between diﬀering military conﬂicts 
in terms of obvious diﬀerences in the type, intensity and dura-
tion of combat exposure (Vietnam vs. Iraq/Afghanistan 
Wars). Finally, this review included a large number of studies 
consisting of variable control groups and relating to historical 
conﬂicts that occurred more than 40 years ago, which raises 
some concern about the reliability of diagnoses and outcome 
reporting.
e limitations we have identiﬁed within the existing lit-
erature highlight the need for prospective cohort studies of 
combat veterans who were engaged in recent armed conﬂicts. 
ese future studies should be designed in such a way that 
combat veterans with TI are compared with an age matched 
control population, without known cardiovascular disease, 
that were deployed to the same operations and at a similar 
time are followed up and reviewed to examine their relative 
cardiovascular risk proﬁles, as well as their psychological 
health. Addressing the evidence deﬁcits identiﬁed above is the 
focus of the ongoing ADVANCE study, which is in the ﬁnal 
phases of its baseline recruitment [56].
In conclusion, there is insuﬃcient data to either support 
or refute an association between combat or combat related TI 
and either CVD or an increased burden of cardiovascular risk 
factors. ere is a weak SOE in support of a link between 
severe combat related TI and CVD and CHD-related death. 
ere is a need for further data from well conducted prospec-
tive cohort studies following recent combat operations.
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development of diabetes, metabolic syndrome, hyperlipidae-
mia, hypertension or increased arterial stiﬀness. Whilst our 
pooled analysis did demonstrate a signiﬁcant association 
between combat related TI and both CVD and CHD related 
death, these data are drawn from only two studies, with a mod-
erate degree of bias, for each of these outcomes. Given these 
facts, coupled with the moderate heterogeneity of the studies 
and their ﬁndings, the strength of evidence to support a link 
remains low.
e decision to additionally examine the published data 
relating to military combat in the absence of signiﬁcant trauma 
on cardiovascular risk and outcomes was important. is was 
done in order to better understand the additive risk associated 
with combat related injury. Pooled data identiﬁed a marginal, 
yet signiﬁcantly lower relative risk of cardiovascular death 
among the combat versus control groups. is is likely to be 
explained by the fact that combatants were likely ﬁtter and 
younger than that of the comparator population of non- 
combat veterans and civilians. ere have been several recent 
publications suggesting a potential link between combat, in 
the absence of TI, and adverse cardiovascular outcomes 
[30–33, 41] and we were keen to more robustly assimilate the 
current evidence.
We deliberately excluded previous studies that examined 
cardiovascular outcomes among selected military populations 
including those with PTSD, isolated traumatic brain and spinal 
injuries. is was undertaken to reduce potential bias. PTSD 
can be triggered by a wide variety of adverse life events includ-
ing military combat [49]. It has been consistently linked to an 
increased cardiovascular risk compared that of ‘non-exposed’ 
individuals [49–53]. is relationship was further endorsed 
in a very recent meta-analysis of Iraq and Afghanistan war 
veterans in which a number of plausible mechanism were 
explored [54]. Traumatic brain and spinal injury have also 
been linked to adverse cardiovascular risk [55]. e studies 
included in our systematic review would have likely contained 
some individuals with these injuries as well as PTSD. However 
this would have represented a far lower proportion of cases 
than that of a selected study of these conditions. For example, 
whilst the burden of PTSD is inﬂuenced by the population 
studied it generally aﬀects about 20% of combat veterans [49]. 
By exploring the wider context of combat and traumatic injury 
(hence multiple injury types) beyond that of lower limb ampu-
tation, which tended to be the main focus of previous studies 
we would be able to appreciate the cumulative eﬀects of these 
exposures including the potentially positive (e.g., related to 
improved ﬁtness for deployments etc.,) and negative (e.g., 
PTSD). is wider population inclusion is critical, given the 
wide range and complexity of traumatic injuries following 
recent armed conﬂicts.
is review has a number of important limitations that 
need to be acknowledged. ere were a large number of cross 
sectional studies and the majority of cohort studies were ret-
rospective. e majority of included studies had a signiﬁcant 
ROB with variable, and in several cases no, adjustment for 
important confounders. Many of the studies did not report 
eﬀect estimates with conﬁdence intervals and there was 
inconsistent reporting of the participant demographics. 
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